Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies
Recent Trends in GLP-1 Use and Spending in Medicare Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, new data from the Centers for Medicare & Medicaid Services (CMS) shows that use and spending for these drugs under Medicare has grown substantially in recent years, reflecting their demonstrated effectiveness at treating type 2 diabetes and other conditions
153 In summary, HNRNPA2B1 emerges as a promising therapeutic target and biomarker for future clinical applications
Steven Patterson, Glasgow Caledonian University, United Kingdom Updates Copyright 2021 Hope, Vincent and Tan
